Circulating Vascular Endothelial Growth Factor (VEGF) Levels in Advanced Stage Cancer Patients Compared to Normal Controls and Diabetes Mellitus Patients with Critical Ischemia
Anti-angiogenic therapy is emerging as a valuable tool in the treatment of patients with cancer. As VEGF is a central target in anti-angiogenic therapy, its levels in the circulation might be relevant in selecting tumor types or patients likely to respond to this treatment. Additional VEGF has bee...
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
AboutScience Srl
2007-12-01
|
Series: | Drug Target Insights |
Subjects: | |
Online Access: | https://journals.aboutscience.eu/index.php/dti/article/view/2025 |
id |
doaj-1a12ad099e8944c88465a6ffdadd4a1f |
---|---|
record_format |
Article |
spelling |
doaj-1a12ad099e8944c88465a6ffdadd4a1f2020-11-25T03:18:09ZengAboutScience SrlDrug Target Insights1177-39282007-12-012110.33393/dti.2007.2025Circulating Vascular Endothelial Growth Factor (VEGF) Levels in Advanced Stage Cancer Patients Compared to Normal Controls and Diabetes Mellitus Patients with Critical IschemiaYoka H. Kusumanto0Coby Meijer1Wendy Dam2Nanno H. Mulder3Geke A.P. Hospers4Dept. of Medical Oncology, University of Groningen and University Medical Center Groningen, Groningen, The NetherlandsDept. of Medical Oncology, University of Groningen and University Medical Center Groningen, Groningen, The NetherlandsDept. of Medical Oncology, University of Groningen and University Medical Center Groningen, Groningen, The NetherlandsDept. of Medical Oncology, University of Groningen and University Medical Center Groningen, Groningen, The NetherlandsDept. of Medical Oncology, University of Groningen and University Medical Center Groningen, Groningen, The Netherlands Anti-angiogenic therapy is emerging as a valuable tool in the treatment of patients with cancer. As VEGF is a central target in anti-angiogenic therapy, its levels in the circulation might be relevant in selecting tumor types or patients likely to respond to this treatment. Additional VEGF has been recognized as a key factor in the pathogenesis of diabetic retinopathy. Recently anti-angiogenic therapy has been advocated in this situation. We measured VEGF levels in whole blood in 42 patients with high grade (n = 26) and low grade (n = 16) end stage cancer, and in 28 healthy controls and 37 patients with diabetes related vascular disease. Only 2/26 patients in the group of high grade cancer had signifi cantly elevated VEGF levels, 1/16 in the low grade group and 1/28 in the healthy control group. In contrast, in 10/37 diabetic patients the mean VEGF levels were signifi cantly elevated compared to the other groups. The mean level in these diabetic patients was signifi cantly elevated compared to the other groups. These data indicate the limitation of the use of circulating VEGF levels as a potential selection criterion for anti-angiogenic therapy in cancer patients and suggest further studies into its application in the management of diabetic complications. https://journals.aboutscience.eu/index.php/dti/article/view/2025VEGF levelcancerdiabetes mellitusCritical Limb Ischemia |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Yoka H. Kusumanto Coby Meijer Wendy Dam Nanno H. Mulder Geke A.P. Hospers |
spellingShingle |
Yoka H. Kusumanto Coby Meijer Wendy Dam Nanno H. Mulder Geke A.P. Hospers Circulating Vascular Endothelial Growth Factor (VEGF) Levels in Advanced Stage Cancer Patients Compared to Normal Controls and Diabetes Mellitus Patients with Critical Ischemia Drug Target Insights VEGF level cancer diabetes mellitus Critical Limb Ischemia |
author_facet |
Yoka H. Kusumanto Coby Meijer Wendy Dam Nanno H. Mulder Geke A.P. Hospers |
author_sort |
Yoka H. Kusumanto |
title |
Circulating Vascular Endothelial Growth Factor (VEGF) Levels in Advanced Stage Cancer Patients Compared to Normal Controls and Diabetes Mellitus Patients with Critical Ischemia |
title_short |
Circulating Vascular Endothelial Growth Factor (VEGF) Levels in Advanced Stage Cancer Patients Compared to Normal Controls and Diabetes Mellitus Patients with Critical Ischemia |
title_full |
Circulating Vascular Endothelial Growth Factor (VEGF) Levels in Advanced Stage Cancer Patients Compared to Normal Controls and Diabetes Mellitus Patients with Critical Ischemia |
title_fullStr |
Circulating Vascular Endothelial Growth Factor (VEGF) Levels in Advanced Stage Cancer Patients Compared to Normal Controls and Diabetes Mellitus Patients with Critical Ischemia |
title_full_unstemmed |
Circulating Vascular Endothelial Growth Factor (VEGF) Levels in Advanced Stage Cancer Patients Compared to Normal Controls and Diabetes Mellitus Patients with Critical Ischemia |
title_sort |
circulating vascular endothelial growth factor (vegf) levels in advanced stage cancer patients compared to normal controls and diabetes mellitus patients with critical ischemia |
publisher |
AboutScience Srl |
series |
Drug Target Insights |
issn |
1177-3928 |
publishDate |
2007-12-01 |
description |
Anti-angiogenic therapy is emerging as a valuable tool in the treatment of patients with cancer. As VEGF is a central target in anti-angiogenic therapy, its levels in the circulation might be relevant in selecting tumor types or patients likely to respond to this treatment. Additional VEGF has been recognized as a key factor in the pathogenesis of diabetic retinopathy. Recently anti-angiogenic therapy has been advocated in this situation. We measured VEGF levels in whole blood in 42 patients with high grade (n = 26) and low grade (n = 16) end stage cancer, and in 28 healthy controls and 37 patients with diabetes related vascular disease. Only 2/26 patients in the group of high grade cancer had signifi cantly elevated VEGF levels, 1/16 in the low grade group and 1/28 in the healthy control group. In contrast, in 10/37 diabetic patients the mean VEGF levels were signifi cantly elevated compared to the other groups. The mean level in these diabetic patients was signifi cantly elevated compared to the other groups. These data indicate the limitation of the use of circulating VEGF levels as a potential selection criterion for anti-angiogenic therapy in cancer patients and suggest further studies into its application in the management of diabetic complications.
|
topic |
VEGF level cancer diabetes mellitus Critical Limb Ischemia |
url |
https://journals.aboutscience.eu/index.php/dti/article/view/2025 |
work_keys_str_mv |
AT yokahkusumanto circulatingvascularendothelialgrowthfactorvegflevelsinadvancedstagecancerpatientscomparedtonormalcontrolsanddiabetesmellituspatientswithcriticalischemia AT cobymeijer circulatingvascularendothelialgrowthfactorvegflevelsinadvancedstagecancerpatientscomparedtonormalcontrolsanddiabetesmellituspatientswithcriticalischemia AT wendydam circulatingvascularendothelialgrowthfactorvegflevelsinadvancedstagecancerpatientscomparedtonormalcontrolsanddiabetesmellituspatientswithcriticalischemia AT nannohmulder circulatingvascularendothelialgrowthfactorvegflevelsinadvancedstagecancerpatientscomparedtonormalcontrolsanddiabetesmellituspatientswithcriticalischemia AT gekeaphospers circulatingvascularendothelialgrowthfactorvegflevelsinadvancedstagecancerpatientscomparedtonormalcontrolsanddiabetesmellituspatientswithcriticalischemia |
_version_ |
1724628521821667328 |